[1]燕法红,邱志远,李乾鹏,等.激活蛋白-1家族JunB、c-Jun、c-Maf、c-Fos在多发性骨髓瘤中的表达[J].医学信息,2021,34(23):44-46.[doi:10.3969/j.issn.1006-1959.2021.23.012]
　YAN Fa-hong,QIU Zhi-yuan,LI Qian-peng,et al.Expression of Activator Protein-1 Family JunB,c-Jun,c-Maf,c-Fos in Multiple Myeloma[J].Medical Information,2021,34(23):44-46.[doi:10.3969/j.issn.1006-1959.2021.23.012]
点击复制

激活蛋白-1家族JunB、c-Jun、c-Maf、c-Fos在多发性骨髓瘤中的表达()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年23期
页码:
44-46
栏目:
论著
出版日期:
2021-12-01

文章信息/Info

Title:
Expression of Activator Protein-1 Family JunB,c-Jun,c-Maf,c-Fos in Multiple Myeloma
文章编号:
1006-1959（2021）23-0044-03
作者:
燕法红; 邱志远; 李乾鹏; 等
（潍坊医学院第一附属医院/潍坊市人民医院血液内科，山东 潍坊 261041）
Author(s):
YAN Fa-hong; QIU Zhi-yuan; LI Qian-peng; et al.
(Department of Hematology,the First Affiliated Hospital of Weifang Medical University/Weifang People’s Hospital,Weifang,261041,Shandong,China)
关键词:
激活蛋白-1; JunB; c-Jun; c-Maf; c-Fos; 多发性骨髓瘤
Keywords:
Activator protein-1; JunB; c-Jun; c-Maf; c-Fos; Multiple myeloma
分类号:
R733.3
DOI:
10.3969/j.issn.1006-1959.2021.23.012
文献标志码:
A
摘要:
目的 观察转录因子激活蛋白-1（AP-1）家族成员JunB、c-Jun、c-Maf、c-Fos在初诊多发性骨髓瘤（MM）中的表达情况。方法 选取我院2019年11月-2020年12月收治的初诊MM患者26例作为MM组，另选同期14例骨髓无恶性细胞的患者作为对照组，应用实时荧光定量PCR（RT-PCR）法检测两组骨髓JunB、c-Jun、c-Maf、c-Fos mRNA的表达水平，比较其差异。结果 MM组JunB mRNA表达水平高于对照组[（0.0845±0.0416）vs（0.0538±0.0181）]，差异有统计学意义（P＜0.05）；MM组c-Jun mRNA表达水平高于对照组[（0.0018±0.0011）vs（0.0005±0.0002）]，差异有统计学意义（P＜0.05）；两组c-Maf mRNA、c-Fos mRNA表达水平比较，差异无统计学意义（P＞0.05）。结论 JunB、c-Jun在多发性骨髓瘤患者中表达上调，可能在其发病中起到一定作用，有望成为新的治疗靶点。
Abstract:
Objective To evaluate the expression levels of activator protein-1 (AP-1) transcription factor member JunB, c-Jun, c-Maf and c-Fos in newly diagnosed multiple myeloma (MM).Methods A total of 26 newly diagnosed MM patients admitted to our hospital from November 2019 to December 2020 were selected as the MM group, and 14 patients with no malignant cells in bone marrow during the same period were selected as the control group. The expression levels of JunB, c-Jun, c-Maf and c-Fos mRNA in bone marrow of the two groups were detected by real-time fluorescence quantitative PCR (RT-PCR), and the differences were compared.Results The JunB mRNA expression level in the MM group was higher than that in the control group [(0.0845±0.0416) vs (0.0538±0.0181)], and the difference was statistically significant (P<0.05). The expression level of c-Jun mRNA in the MM group was higher than that in the control group [(0.0018±0.0011) vs (0.0005±0.0012)], and the difference was statistically significant (P<0.05). There was no significant difference in the expression levels of c-Maf mRNA and c-Fos mRNA between the two groups (P>0.05).Conclusion The expression of JunB and c-Jun is up-regulated in patients with multiple myeloma, which may play a role in its pathogenesis, and is expected to become a new therapeutic target.

参考文献/References:

[1]中国医师协会血液科医师分会.中国多发性骨髓瘤诊治指南（2020年修订）[J].中华内科杂志,2020,59(5):341-346.[2]范凤娟,江沁月,孙春艳,等.《转录因子JunB/AP-1调节多发性骨髓瘤在骨髓微环境中的细胞增殖与耐药》解读[J].临床血液学杂志,2018,31(7):491-494.[3]Fan F,Podar K.The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology[J].Cancers (Basel),2021,13(10):2326.[4]Fan F,Bashari MH,Morelli E,et al.The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment[J].Leukemia,2017,31(7):1570-1581.[5]Fan F,Malvestiti S,Vallet S,et al.JunB is a key regulator of multiple myeloma bone marrow angiogenesis[J].Leukemia,2021,35(12):3509-3525.[6]Yoshitomi Y,Ikeda T,Saito-Takatsuji H,et al.Emerging Role of AP-1 Transcription Factor JunB in Angiogenesis and Vascular Development[J].Int J Mol Sci,2021,22(6):2804.[7]Kenner L,Hoebertz A,Beil FT,et al.Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects[J].J Cell Biol,2004,164(4):613-623.[8]Leventaki V,Drakos E,Karanikou M.c-JUN N-terminal kinase (JNK) is activated and contributes to tumor cell proliferation in classical Hodgkin lymphoma[J].Hum Pathol,2014,45(3):565-572.[9]Miannay B,Minvielle S,Roux O,et al.Logic programming reveals alteration of key transcription factors in multiple myeloma[J].Sci Rep,2017,7(1):9257.[10]Chen L,Wang S,Zhou Y,et al.Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma[J].Blood,2010,115(1):61-70.[11]Fan F,Tonon G,Bashari MH,et al.Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation[J].Cancer Lett,2014,343(2):286-294.[12]Saha MN,Jiang H,Yang Y,et al.Targeting p53 via JNK pathway: a novel role of RITA for apoptotic signaling in multiple myeloma[J].PLoS One,2012,7(1):e30215.[13]Rasmussen T,Knudsen LM,Dahl IM,et al.C-MAF oncogene dysregulation in multiple myeloma: frequency and biological relevance[J].Leuk Lymphoma,2003,44(10):1761-1766.[14]徐冬,吕晓伟,毕作木,等.沉默c-maf基因对多发性骨髓瘤细胞系 RPMI8226增殖和侵袭力的影响[J].中国肿瘤临床,2014,41(14):890-894.[15]Qiang YW,Ye S,Chen Y,et al.MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma[J].Blood,2016,128(25):2919-2930.

更新日期/Last Update: 1900-01-01